China: China Solicits Comments On Drug GCP

Last Updated: 21 December 2016
Article by Katherine Wang

The China Food and Drug Administration (“CFDA”) recently proposed revisions to the Good Clinical Practices for Pharmaceuticals (“GCP”), the most comprehensive revision in 13 years. The revisions (“Revisions”) are now open to public comments until January 31, 2017.

It’s notable that the Revisions have rewritten all the articles of the current GCP, but these sweeping changes are not especially innovative, as most of the concepts and principles have already been addressed in the International Conference on Harmonisation (“ICH”) GCP.

Overall, the Revisions set forth general principles of conducting clinical studies in China, as well as guidance of roles and responsibilities for the ethics committee (“EC”), the investigator and the sponsor, as well as the requirements for protocol and investigator’s brochure (“IB”). Highlights of the changes proposed in the Revisions are as follows:

  • Regulate the Handling and Retention of Biological Specimens: According to the Revisions, the sponsor shall be prohibited from conducting any testing that is unrelated to the study protocol approved by the EC on biological specimens. Additionally, the Revisions would require the sponsor to seek written consent from the subjects regarding the continuous storage of and/or possible use in any future research of leftover biological specimens after completion of the trial. The consent form would have to specify issues such as the retention period, the data confidentiality requirements, and the circumstances under which the data and specimens could be shared with other investigators.
  • Extend Insurance Coverage to Institutions: Unlike the current GCP, the Revisions would require the sponsor to insure or indemnify both the investigator and the institution against all claims, except for those arising from malpractice.
  • Allow an Individual to Serve as Sponsor or CRO: As a response to the pilot program of marketing authorization holder promulgated by the State Council this past June, the Revisions would allow individuals to act as sponsors and contract research organizations (“CROs”).
  • Specify the Requirement and Quantity of Retention Samples: Under the Revisions, reserve samples of study drugs for bioequivalence and bioavailability testing must be retained at the study site for no less than two years after marketing approval. The investigator will randomly select the reserve samples from the supply sent by the sponsor and should retain enough to allow five rounds of quality standard testing.
  • Detail the Process of Seeking Informed Consent from Subjects: Under the Revisions, the EC would have to pre-approve any new information that may affect subjects’ willingness to participate in the study. Importantly, the Revisions would prohibit agreements (whether oral or written) that ask subjects to waive their legal rights, or that may release the investigator, the institution, the sponsor, or its agents from liability.
  • Add Notification Requirement of the Unblinding Results: The Revisions propose that, for any double-blinding studies, the sponsor must provide the investigator and all study participants with the treatment allocation status after unblinding.
  • Revise the Data Retention Requirement: Whilst the current GCP imposes different data retention requirements on the investigator (e.g., five years after the study ends) and the sponsor (e.g., five years after obtaining marketing approval), the Revisions would impose similar obligations on both: data would have to be retained for two years after marketing approval or for five years after the study ends.
  • Require to Specify Direct Access to Source Records: The Revisions would require that under either the protocol or the clinical trial agreement ("CTA”), the investigator and the institution must be required to give the monitors and auditors direct access to the source data and source documents related to the clinical trial. This change may help clarify the industry’s concern regarding who may have access to subjects’ medical records to verify the authenticity of the study data, especially for the clinical trial data inspection campaign.
  • Clarify Contractual Arrangements Regarding CTA: The Revisions clearly stipulate that a CTA shall be structured as a three-party agreement between the sponsor, the investigator and the institution. Each party shall sign the CTA on his/her own capacity. In addition, for multi-center trials, the Revisions specify that the sponsor shall sign the CTA with all participating investigators and the relevant institutions.
  • Impose Regular Review Requirement of IB: The requirement regarding the IB in the current GCP is simple and general. The Revisions would incorporate the same detailed regulatory requirement on IB as that provided in the ICH GCP. In particular, according to the Revisions the sponsor must establish a written procedure regarding amendments to the IB, noting that the IB needs to undergo a review and amendment at least once per year. In addition, the Revisions add several provisions to set forth the purpose, general considerations, and contents regarding the IB.
  • Adopt Some Changes Reflected in the Latest ICH GCP: The latest version of the ICH GCP, the E6 (R2), was adopted by the ICH on November 9, 2016. Accordingly, the Revisions include a number of the new changes reflected in the E6 (R2), such as the notions of certified copies and validation of computerized systems, as well as the sections regarding quality management, risk management, oversight of CROs, and risk-based monitoring, among others. To some extent, it reflects CFDA’s willingness to establish a regulatory framework in line with international standards.

The Revisions would standardize the conduct of drug studies in China, as well as strengthen the management of such studies. It remains unclear whether and when these changes will be adopted. We recommend that pharmaceutical companies closely monitor the progress of the Revisions and propose their comments by the deadline.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
 
Some comments from our readers…
“The articles are extremely timely and highly applicable”
“I often find critical information not available elsewhere”
“As in-house counsel, Mondaq’s service is of great value”

Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement

Mondaq.com (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of www.mondaq.com

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about Mondaq.com’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.

Disclaimer

Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.

Registration

Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to unsubscribe@mondaq.com with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.

Cookies

A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.

Links

This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.

Mail-A-Friend

If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.

Emails

From time to time Mondaq may send you emails promoting Mondaq services including new services. You may opt out of receiving such emails by clicking below.

*** If you do not wish to receive any future announcements of services offered by Mondaq you may opt out by clicking here .

Security

This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to webmaster@mondaq.com.

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to EditorialAdvisor@mondaq.com.

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at enquiries@mondaq.com.

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at problems@mondaq.com and we will use commercially reasonable efforts to determine and correct the problem promptly.